These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11115952)

  • 1. Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
    Tuldrà A; Fumaz CR; Ferrer MJ; Bayés R; Arnó A; Balagué M; Bonjoch A; Jou A; Negredo E; Paredes R; Ruiz L; Romeu J; Sirera G; Tural C; Burger D; Clotet B
    J Acquir Immune Defic Syndr; 2000 Nov; 25(3):221-8. PubMed ID: 11115952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
    Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G
    Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study.
    Rathbun RC; Farmer KC; Stephens JR; Lockhart SM
    Clin Ther; 2005 Feb; 27(2):199-209. PubMed ID: 15811483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS.
    Haddad M; Inch C; Glazier RH; Wilkins AL; Urbshott G; Bayoumi A; Rourke S
    Cochrane Database Syst Rev; 2000; (3):CD001442. PubMed ID: 10908497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
    Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
    Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.
    Duval X; Mentré F; Lamotte C; Chêne G; Spire B; Dellamonica P; Panhard X; Salmon D; Raffi F; Peytavin G; Leport C;
    Ther Drug Monit; 2005 Feb; 27(1):63-70. PubMed ID: 15665749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
    Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managed problem solving for antiretroviral therapy adherence: a randomized trial.
    Gross R; Bellamy SL; Chapman J; Han X; O'Duor J; Palmer SC; Houts PS; Coyne JC; Strom BL
    JAMA Intern Med; 2013 Feb; 173(4):300-6. PubMed ID: 23358784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment.
    Palepu A; Horton NJ; Tibbetts N; Meli S; Samet JH
    Addiction; 2004 Mar; 99(3):361-8. PubMed ID: 14982549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
    Ruiz L; Negredo E; Domingo P; Paredes R; Francia E; Balagué M; Gel S; Bonjoch A; Fumaz CR; Johnston S; Romeu J; Lange J; Clotet B;
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):229-36. PubMed ID: 11464141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention.
    Wohl AR; Garland WH; Valencia R; Squires K; Witt MD; Kovacs A; Larsen R; Hader S; Anthony MN; Weidle PJ
    Clin Infect Dis; 2006 Jun; 42(11):1619-27. PubMed ID: 16652320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
    Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.